Protocol Ledger

NCT03558152 · Phase II · COMPLETED

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of UTTR1147A Compared With Placebo and With Vedolizumab in Participants With Moderate to Severe Ulcerative Colitis (UC)

Interventional Phase II clinical trial protocol NCT03558152 sponsored by Roche / Genentech in Immunology, Rheumatology, and Dermatology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2018-10-26 Enrollment: 195 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03558152
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)195 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03558152
Protocol FieldVerified Registry Value
NCT IdentifierNCT03558152
Consolidated Lead SponsorRoche / Genentech
Therapeutic Condition CohortImmunology, Rheumatology, and Dermatology
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment195 participants (ACTUAL)
Registered Start Date2018-10-26
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT03558152
Hospital Research SiteLocationSite Profile
Huntsman Cancer Institute at University of UtahSalt Lake City, UTOpen Hospital Dossier ->
Azienda Ospedaliera Di PadovaPadova, ItalyOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Roche / Genentech across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI